AbbVie Inc.
AbbVie Seeks EU Approval for Crohn's Disease Treatment Expansion
·Consolidated from 3 sources
AbbVie has filed an application with the European Medicines Agency (EMA) seeking to expand the label for its Crohn's disease treatment, Skyrizi. The submission focuses on a subcutaneous induction option for adult patients with moderately to severely active disease. This move aims to broaden the accessibility and application of Skyrizi in the European market.
AbbVie Inc. is advancing its European regulatory strategy with a new filing for its immunology drug, Skyrizi. The company announced it has submitted an application to the European Medicines Agency (EMA) for a label expansion that would include a subcutaneous induction option for adult patients suffering from moderately to severely active Crohn's disease. This represents a significant step in potentially making the treatment more convenient for a wider patient population in the region.
The filing specifically targets the administration of Skyrizi via subcutaneous injection for the induction phase of treatment. Currently, Skyrizi is approved for Crohn's disease in several markets, but this application seeks to broaden its utility by offering a different delivery method for initiating therapy. Coverage today notes this regulatory submission is a key part of AbbVie's ongoing efforts to enhance its immunology portfolio and address unmet needs in gastrointestinal conditions.
Beyond its specific drug development news, AbbVie was also highlighted in broader market commentary regarding investment strategies during inflationary periods. One report identified the company as a potential "dividend aristocrat" stock suitable for long-term ownership, suggesting its financial stability and commitment to shareholder returns are considered attractive attributes by some investors. This broader market perception, while not directly related to the Crohn's disease filing, contributes to the overall financial narrative surrounding the company.
The EMA's review process will determine if the subcutaneous induction option for Skyrizi receives approval. If successful, it could lead to increased adoption of the therapy among European physicians and patients managing Crohn's disease, further solidifying AbbVie's presence in the competitive immunology sector. The company continues to invest in research and development across its therapeutic areas, aiming to bring innovative treatments to market.
Sources
This recap was generated by consolidating the public headlines below.
- When Inflation Is Sticky, 5 Dividend Aristocrats Are the Stocks to Own Now and ForeverAug 27, 2026
- AbbVie (ABBV) Filed For EU Crohn's Disease Label ExpansionAug 27, 2026
- AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's DiseaseAug 27, 2026